BEATCF enrolment tables

Edward Pan

21 February, 2024

Table 1: **Demographics and Clinical Baseline Characteristics**

Characteristic	**Overall**, N = 872	ppFEV1>70 No Pseudomonas N=531	ppFEV1>70 Pseudomonas N=228	ppFEV1<70 No Pseudomonas N=32	ppFEV1<70 Pseudomonas N=72
Median age in years (IQR)					
Median (IQR)	11 (6, 17)	10 (5, 14)	13 (7, 17)	29 (17, 42)	32 (23, 43)
Age Groups					
<6y	180 (21%)	136 (26%)	41 (18%)	1 (3.1%)	2 (2.8%)
6y-<12y	262 (30%)	191 (36%)	64 (28%)	4 (13%)	1 (1.4%)
12y-<18y	219 (25%)	132 (25%)	71 (31%)	4 (13%)	9 (13%)
18y-<30y	96 (11%)	48 (9.0%)	19 (8.3%)	9 (28%)	19 (26%)
30y-<40y	59 (6.8%)	14 (2.6%)	21 (9.2%)	4 (13%)	20 (28%)
>=40y	56 (6.4%)	10 (1.9%)	12 (5.3%)	10 (31%)	21 (29%)
Mean height in cm (SD)	141 (31)	135 (31)	144 (29)	162 (21)	164 (14)
(Missing)	1	1	0	0	0
Mean weight in kilograms (SD)	43 (23)	38 (22)	44 (22)	62 (22)	63 (17)
BMI kg/m^2 (SD)	19.6 (4.3)	18.9 (4.0)	19.6 (4.1)	22.4 (4.3)	23.0 (4.4)
(Missing)	1	1	0	0	0
Sex					
Female	425 (49%)	255 (48%)	116 (51%)	15 (47%)	37 (51%)
Male	447 (51%)	276 (52%)	112 (49%)	17 (53%)	35 (49%)
Genotype					
Heterozygous F508del	381 (50%)	257 (54%)	87 (43%)	16 (64%)	19 (38%)
Homozygous F508del	317 (42%)	176 (37%)	104 (52%)	6 (24%)	26 (52%)
Other	61 (8.0%)	43 (9.0%)	10 (5.0%)	3 (12%)	5 (10%)
(Missing)	113	55	27	7	22
Sweat Chlorine Level in mmol/L					
<40	27 (3.2%)	21 (4.1%)	5 (2.2%)	1 (3.2%)	0 (0%)
40-<60	20 (2.4%)	19 (3.7%)	1 (0.4%)	0 (0%)	0 (0%)
>=60	153 (18%)	100 (19%)	43 (19%)	4 (13%)	3 (4.3%)
CFTR modulator	273 (32%)	143 (28%)	69 (31%)	18 (58%)	41 (59%)
Enrolment before Aug2022	376 (44%)	234 (45%)	105 (47%)	8 (26%)	25 (36%)
(Missing)	23	14	5	1	3
Pancreatic Insufficiency	638 (73%)	374 (70%)	188 (82%)	16 (50%)	53 (74%)
CF diabetes mellitus	110 (13%)	38 (7.2%)	38 (17%)	10 (31%)	24 (33%)
C.difficile (identified in the previous 2 years)	1 (0.1%)	1 (0.2%)	0 (0%)	0 (0%)	0 (0%)
Total IgE					
Median (IQR)	41 (14, 172)	37 (15, 151)	61 (14, 227)	65 (27, 253)	36 (15, 126)
(Missing)	430	252	100	26	45
Highest ppFEV in previous 12 months	90 (20)	97 (12)	95 (13)	55 (11)	52 (11)
(Missing)	158	114	35	0	0
Highest ppFEV in the previous 6 months	88 (20)	95 (13)	93 (13)	54 (11)	50 (12)
(Missing)	176	127	39	0	1

[1] n (%); Mean (SD)

Table 2: **CFQR Ages 12 and 13 at Enrolment (60 days)**

Characteristic	**Overall**, N = 67	ppFEV1>70 No Pseudomonas N=47	ppFEV1>70 Pseudomonas N=17	ppFEV1<70 No Pseudomonas N=1	ppFEV1<70 Pseudomonas N=2
Physical	86 (19)	87 (17)	84 (21)	100 (NA)	50 (31)
Emotional	72 (14)	73 (13)	68 (15)	92 (NA)	67 (6)
Social	71 (19)	74 (17)	62 (18)	86 (NA)	64 (51)
Body	84 (18)	86 (19)	81 (17)	67 (NA)	78 (16)
Eat	83 (21)	88 (16)	76 (24)	33 (NA)	56 (47)
Treatment burden	70 (19)	71 (19)	67 (22)	67 (NA)	72 (8)
Respiration	82 (15)	84 (16)	81 (14)	83 (NA)	63 (6)
Digestion	71 (22)	72 (22)	67 (24)	100 (NA)	67 (0)

[1] Mean (SD)

Table 3: **CFQR Adolescents and Adults at Enrolment (60 days)**

Characteristic	**Overall**, N = 227	ppFEV1>70 No Pseudomonas N=91	ppFEV1>70 Pseudomonas N=70	ppFEV1<70 No Pseudomonas N=18	ppFEV1<70 Pseudomonas N=48
Physical	75 (25)	82 (20)	77 (23)	72 (25)	59 (30)
Role	79 (20)	83 (16)	75 (22)	81 (20)	74 (22)
Vitality	55 (19)	58 (19)	55 (20)	56 (19)	49 (19)
Emotional	73 (21)	75 (20)	72 (23)	83 (13)	70 (19)
Social	69 (21)	73 (19)	67 (23)	66 (17)	65 (21)
Body	72 (24)	73 (25)	72 (24)	80 (21)	68 (24)
Eat	88 (20)	88 (21)	87 (22)	98 (4)	86 (18)
Treatment burden	66 (23)	71 (20)	61 (26)	69 (19)	63 (25)
Health perceptions	69 (22)	76 (19)	65 (25)	69 (22)	61 (22)
Weight	78 (33)	83 (29)	72 (35)	91 (19)	73 (38)
Respiration	73 (21)	79 (19)	72 (20)	68 (24)	66 (24)
Digestion	78 (19)	81 (18)	78 (19)	76 (24)	74 (19)

[1] Mean (SD)

Table 4: **CFQR Parents and Caregivers at Enrolment (60 days)**

Characteristic	Overall, N = 215	ppFEV1>70 No Pseudomonas N=159	ppFEV1>70 Pseudomonas N=51	ppFEV1<70 No Pseudomonas N=4	ppFEV1<70 Pseudomonas N=1
Physical	85 (15)	87 (15)	81 (17)	74 (12)	70 (NA)
Emotional	81 (17)	81 (17)	80 (18)	88 (19)	60 (NA)
School	75 (22)	76 (22)	73 (21)	64 (26)	67 (NA)
Body	77 (26)	78 (25)	75 (26)	72 (35)	67 (NA)
Eat	72 (27)	74 (27)	68 (29)	58 (42)	67 (NA)
Treatment burden	63 (24)	67 (23)	51 (21)	50 (29)	44 (NA)
Health perceptions	79 (19)	81 (18)	74 (22)	86 (21)	78 (NA)
Weight	63 (37)	63 (38)	64 (37)	58 (42)	33 (NA)
Respiration	85 (16)	88 (14)	79 (18)	83 (10)	72 (NA)
Digestion	77 (18)	79 (18)	70 (18)	83 (11)	89 (NA)

[1] Mean (SD)

Table 5: **Concomitant medications at enrolment**

Group	Medication Name	Overall N=872	ppFEV1>70 No Pseudomonas N=531	ppFEV1>70 Pseudomonas N=228	ppFEV1<70 No Pseudomonas N=32	ppFEV1<70 Pseudomonas N=72
Antibiotics	**Azithromycin**	213 (24%)	83 (16%)	73 (32%)	13 (41%)	43 (60%)
	Tobramycin	135 (15%)	33 (6.2%)	64 (28%)	9 (28%)	27 (38%)
	Amoxicillin	103 (12%)	77 (15%)	24 (11%)	1 (3.1%)	1 (1.4%)
	Flucloxacillin	44 (5.0%)	31 (5.8%)	11 (4.8%)	0 (0%)	2 (2.8%)
	Cotrimoxazole	33 (3.8%)	18 (3.4%)	11 (4.8%)	1 (3.1%)	3 (4.2%)
	Ciprofloxacin	32 (3.7%)	11 (2.1%)	12 (5.3%)	1 (3.1%)	8 (11%)
	Other	79 (9.1%)	22 (4.1%)	33 (14%)	7 (22%)	17 (24%)
Antifungal	**Antifungal**	30 (3.4%)	12 (2.3%)	11 (4.8%)	2 (6.3%)	4 (5.6%)
Corticosteroids	**Inhaled**	259 (30%)	114 (21%)	88 (39%)	12 (38%)	41 (57%)
	Nasal	73 (8.4%)	40 (7.5%)	22 (9.6%)	1 (3.1%)	10 (14%)
	Systemic	23 (2.6%)	8 (1.5%)	8 (3.5%)	0 (0%)	7 (9.7%)
	Topical	5 (0.6%)	5 (0.9%)	0 (0%)	0 (0%)	0 (0%)
Muco-active agents	**Dornase Alfa**	588 (67%)	329 (62%)	185 (81%)	22 (69%)	46 (64%)
	Hypertonic saline	466 (53%)	252 (47%)	151 (66%)	17 (53%)	41 (57%)
	Mannitol Bronchitol	48 (5.5%)	31 (5.8%)	12 (5.3%)	0 (0%)	5 (6.9%)
CFTR modulators	**Elexacaftor/tezacaftor/ivacaftor (Trikafta)**	213 (24%)	97 (18%)	60 (26%)	17 (53%)	38 (53%)
	Lumacaftor/ivacaftor (Orkambi)	152 (17%)	104 (20%)	39 (17%)	1 (3.1%)	7 (9.7%)
	Tezacaftor/ivacaftor (symdeko)	85 (9.7%)	34 (6.4%)	32 (14%)	3 (9.4%)	14 (19%)
	Ivacaftor (Kalydeco)	49 (5.6%)	33 (6.2%)	5 (2.2%)	2 (6.3%)	8 (11%)
Antidepressants/Antipsychotic	**Antidepressant**	55 (6.3%)	22 (4.1%)	14 (6.1%)	4 (13%)	13 (18%)
	Antipsychotic	11 (1.3%)	4 (0.8%)	6 (2.6%)	0 (0%)	1 (1.4%)
	ADHD medication	11 (1.3%)	8 (1.5%)	3 (1.3%)	0 (0%)	0 (0%)
Other	**Vitamin/mineral supplements**	683 (78%)	401 (76%)	191 (84%)	23 (72%)	61 (85%)
	Pancreatic enzyme replacement	682 (78%)	392 (74%)	198 (87%)	21 (66%)	64 (89%)
	Sodium chloride	392 (45%)	265 (50%)	108 (47%)	4 (13%)	12 (17%)
	Bronchodilator (Salbutamol)	372 (43%)	178 (34%)	125 (55%)	15 (47%)	49 (68%)
	Proton pump inhibitor	182 (21%)	89 (17%)	54 (24%)	6 (19%)	31 (43%)
	Insulin medication	84 (9.6%)	30 (5.6%)	26 (11%)	8 (25%)	20 (28%)
	Ursodeoxycholic acid	73 (8.4%)	32 (6.0%)	25 (11%)	4 (13%)	11 (15%)
	Iron supplement	66 (7.6%)	34 (6.4%)	15 (6.6%)	3 (9.4%)	13 (18%)

[1] n (%)

Table 6: **Microbiology (Bacteria) at enrolment**

Microbiology	Overall N=872	ppFEV1>70 No Pseudomonas N=531	ppFEV1>70 Pseudomonas N=228	ppFEV1<70 No Pseudomonas N=32	ppFEV1<70 Pseudomonas N=72
Pseudomonas species	304 (35%)	0 (0%)	228 (100%)	0 (0%)	72 (100%)
Staphylococcus species	497 (57%)	306 (58%)	145 (64%)	10 (31%)	33 (46%)
Haemophilus species	193 (22%)	135 (25%)	51 (22%)	2 (6.3%)	5 (6.9%)
Stenotrophomonas species	100 (11%)	36 (6.8%)	48 (21%)	5 (16%)	11 (15%)
Mycobacterium species	42 (4.8%)	18 (3.4%)	18 (7.9%)	2 (6.3%)	4 (5.6%)
Streptococcus pneumoniae	39 (4.5%)	29 (5.5%)	7 (3.1%)	0 (0%)	3 (4.2%)
Streptococccus pyogenes	18 (2.1%)	10 (1.9%)	7 (3.1%)	0 (0%)	1 (1.4%)
Streptococccus species (Other)	14 (1.6%)	10 (1.9%)	3 (1.3%)	0 (0%)	1 (1.4%)
Escherichia species	33 (3.8%)	25 (4.7%)	7 (3.1%)	0 (0%)	1 (1.4%)
Klebsiella species	33 (3.8%)	18 (3.4%)	14 (6.1%)	1 (3.1%)	0 (0%)
Chryseobacterium species	31 (3.6%)	11 (2.1%)	15 (6.6%)	2 (6.3%)	3 (4.2%)
Enterobacter species	30 (3.4%)	18 (3.4%)	12 (5.3%)	0 (0%)	0 (0%)
Moraxella species	27 (3.1%)	21 (4.0%)	6 (2.6%)	0 (0%)	0 (0%)
Acinetobacterium species	26 (3.0%)	12 (2.3%)	13 (5.7%)	0 (0%)	1 (1.4%)
Achromobacter species	25 (2.9%)	7 (1.3%)	10 (4.4%)	3 (9.4%)	4 (5.6%)
Serratia species	23 (2.6%)	12 (2.3%)	10 (4.4%)	1 (3.1%)	0 (0%)
Burkholderia species	20 (2.3%)	13 (2.4%)	1 (0.4%)	1 (3.1%)	5 (6.9%)
Other	96 (11%)	46 (8.7%)	43 (19%)	3 (9.4%)	4 (5.6%)

[1] n (%)

Table 7: **Microbiology (Virus) at enrolment**

Microbiology	Overall N=872	ppFEV1>70 No Pseudomonas N=531	ppFEV1>70 Pseudomonas N=228	ppFEV1<70 No Pseudomonas N=32	ppFEV1<70 Pseudomonas N=72
Rhinovirus	39 (4.5%)	17 (3.2%)	16 (7.0%)	2 (6.3%)	4 (5.6%)
SARS-CoV-2	20 (2.3%)	10 (1.9%)	6 (2.6%)	0 (0%)	4 (5.6%)
Parainfluenza (PIV)	16 (1.8%)	8 (1.5%)	7 (3.1%)	0 (0%)	1 (1.4%)
Synctial (RSV)	16 (1.8%)	10 (1.9%)	6 (2.6%)	0 (0%)	0 (0%)
Enterovirus	8 (0.9%)	5 (0.9%)	3 (1.3%)	0 (0%)	0 (0%)
Adenovirus	6 (0.7%)	3 (0.6%)	3 (1.3%)	0 (0%)	0 (0%)
Influenza	5 (0.6%)	4 (0.8%)	1 (0.4%)	0 (0%)	0 (0%)
Other	3 (0.3%)	2 (0.4%)	0 (0%)	0 (0%)	1 (1.4%)

[1] n (%)

Table 8: **Microbiology (Fungi) at enrolment**

Microbiology	Overall N=872	ppFEV1>70 No Pseudomonas N=531	ppFEV1>70 Pseudomonas N=228	ppFEV1<70 No Pseudomonas N=32	ppFEV1<70 Pseudomonas N=72
Aspergillus species	194 (22%)	93 (18%)	82 (36%)	4 (13%)	13 (18%)
Candida species	174 (20%)	84 (16%)	62 (27%)	7 (22%)	20 (28%)
Other	102 (12%)	58 (11%)	35 (15%)	2 (6.3%)	6 (8.3%)

[1] n (%)